Onco-hematology Molecular Testing Market Size to Reach USD 1.5 billion by 2031 with a 12.5% CAGR, Boosted by Next-Generation Blood Cancer Diagnostics| Exclusive Report by Transparency Market Research, Inc.
October 03, 2024 23:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc., Oct. 03, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global onco-hematology...
CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program
December 09, 2023 00:00 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients,...
CURE Media Group® announces Jane Fonda as keynote speaker for the 2023 MPN Heroes® recognition program
November 16, 2023 10:38 ET
|
CURE Media Group
CURE and Incyte Corporation are proud to host the 2023 MPN Heroes recognition ceremony, an evening of gratitude and celebration of the heroes who have made a significant impact in the lives of...
CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program
December 09, 2022 11:00 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients,...
CURE Media Group announces Vanessa Bayer as keynote speaker for the 2022 MPN Heroes® Recognition Program
December 02, 2022 17:41 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients,...
Inaugural Sole 2 Soul for MPN™ Trek Set For August 3-7, 2022 in Waterton Lakes National Park in Canada
August 03, 2022 08:01 ET
|
CURE Media Group
CRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients,...
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
May 03, 2022 08:00 ET
|
Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Imago BioSciences to Host Virtual Investor Event
December 01, 2021 08:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
November 11, 2021 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
November 10, 2021 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...